AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00530491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast track lung surgery
Description: fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
Study NCT00444418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
Study NCT00444418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
Study NCT00444418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
Study NCT00444418 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
Study NCT00735098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KBA exercise
Description: KBA exercise protocol, 3 times per week for 8 weeks
Study NCT00735098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training exercise
Description: strength training exercise, 3 times per week for 8 weeks
Study NCT00735098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KBA and strength training
Description: KBA and strength training exercise, 3 times per week for 8 weeks
Study NCT00735098 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 8 week control group
Study NCT04703062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 1
Description: It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
Study NCT04703062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 2
Description: Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
Study NCT04290260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of breast bra
Description: Patients will use a breast from admission to hospital discharge
Study NCT04290260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (not use of bra)
Study NCT00333970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: individual cognitive training
Study NCT03582852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of genital prolapse
Description: Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
Study NCT00956462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac (NSAID) versus Dexamethasone (steroid)
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device
Study NCT00956462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac (NSAID) versus Dexamethasone (steroid)
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device
Study NCT02302755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP10
Description: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
Study NCT00049140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Study NCT00049140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioluminescence
Study NCT00049140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00049140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00049140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT02637648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: parallel Group administration
Study NCT02637648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: parallel Group administration
Study NCT00829062 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Continuous glucose glucose sensor- physician ordered
Description: Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
Study NCT01995422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: One hour sessions of active walking occurring three times a week during three months
Study NCT04439812 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
Study NCT02952898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC 695
Description: GDC 695 is a topical gel.
Study NCT02952898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Gel, 3%
Description: Diclofenac sodium gel, 3% is an FDA-approved drug.
Study NCT02952898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
Study NCT04173832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi Pingchan Granule Combined With Amantadine
Description: Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
Study NCT04173832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Combined With Amantadine
Description: Placebo and Amantadine are given to patients simultaneously
Study NCT00110526 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad.hIL-12
Description: Ad.hIL-12 intraprostatic injection IND
Study NCT04020757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: variation in dialysis bicarbonate
Description: 35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
Study NCT04020757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zone Perfect bar
Description: 16g protein supplement given during first 30 mins of dialysis on last testing day
Study NCT03603379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C225-ILs-dox
Description: C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
Study NCT00229983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
Study NCT01716715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01716715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01716715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01018589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix cream
Description: We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application.
Study NCT02748967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
Study NCT02748967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.
Study NCT01006694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation + Medication
Description: Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
Study NCT01006694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Antidepressant Medication
Description: Guideline Antidepressant Medication, following the VN National Mental Health plan.
Study NCT02079545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-AI)
Description: Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
Study NCT02079545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-U)
Description: Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
Study NCT02079545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-AI)
Description: Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
Study NCT02403492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP
Description: All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
Study NCT02403492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP, Continuation
Description: Participants will be randomized to continue cPAP for a 2 week period
Study NCT02403492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP, Discontinuation
Description: Participants will be randomized to discontinue cPAP for a 2 week period
Study NCT02555683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 150 mg once daily
Study NCT02555683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 450 mg once daily
Study NCT02555683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT03465306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
Study NCT03465306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided
Description: Self-guided refers to any contact between the participants and a therapist or coach.
Study NCT02314702 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® L Revision Femoral Stem
Description: Revision Total Hip Arthroplasty
Study NCT01367210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc, Darunavir/r
Description: Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
Study NCT01367210 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: current antiretroviral therapy with 3 drugs
Description: To continue the assumption of previous HAART
Study NCT01877265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01245660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAPATINIB
Description: Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
Study NCT02949037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Care Environment (MHCE)
Description: An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
Study NCT01235143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
Study NCT01235143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
Study NCT01947582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle foot orthosis
Description: The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
Study NCT02082275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OB Nest
Description: * Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires.
Study NCT01224860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
Study NCT01224860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
Study NCT00522197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-herbal agent ACAPHA
Study NCT00522197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study NCT03098953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: one drop per eye for each eye
Study NCT04645875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit regimen
Description: See Sit regimen arm description
Study NCT04645875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SitLess regimen
Description: See SitLess regimen arm description
Study NCT01560364 — intervention group
Intervention type: OTHER
Intervention: renal replacement therapy
Description: Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
Study NCT04167644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Rankin Scale (mRS)
Description: Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
Study NCT00706823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel airway (Intersurgical Ltd., Wokingham, England)
Description: supra-glottic airway device
Study NCT00706823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway-Unique
Description: supra-glottic airway device
Study NCT04112056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)
Description: It is same as that stated in arm description.
Study NCT03719885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear Intranasal Tear Neurostimulator
Description: This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
Study NCT00937326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
Study NCT03346785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Photography
Description: Participants will engage in food photography on their smart phones while eating
Study NCT03346785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Food Photography
Description: Participants will engage in non-food photography on their smart phones while eating
Study NCT03346785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Phone Use
Description: Participants will not use their smart phones while eating
Study NCT00798499 — intervention group
Intervention type: OTHER
Intervention: Laboratory variables
Description: 1 visit
Study NCT05329974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer guided buccal cortical plate separation
Description: Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
Study NCT02656784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
Study NCT02656784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
Study NCT00612040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
Study NCT00612040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
Study NCT00612040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, injection s.c., once daily
Study NCT00612040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
Study NCT03169556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-laryngoscope guided lightwand
Description: After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
Study NCT03169556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lightwand alone
Description: After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
Study NCT01874613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRC implant reconstruction
Description: A cranioplasty with the FRC implant is performed.
Study NCT01874613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRC implant reconstruction
Description: The orbital floor fracture is reconstructed with the FRC implant.
Study NCT02131194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lenstatin
Description: Dietary Supplement Lenstatin